Horizon Results of Phase 3 Trial at American Clinical Endocrinologists Assn

Horizon Pharma plc (Nasdaq: HZNP) today announced that it will present additional results from its Phase 3 confirmatory clinical trial (OPTIC) evaluating teprotumumab for the treatment of active thyroid eye disease (TED) at the 2019 American Association of Clinical Endocrinologists (AACE) 28^th Annual Scientific & Clinical Congress. The late-breaking oral presentation will be presented on Friday, April 26, 2019.
Positive primary endpoint data from the clinical trial, titled OPTIC (Treatment of Graves’ Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis with Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study), was announced on February 28, 2019. Detailed new data will be presented at the meeting.
Presentation Details:

• Title: Teprotumumab treatment effect on proptosis in patients with active thyroid eye disease: Results from a Phase 3, randomized, double-masked, placebo-controlled, parallel-group, multicenter study
• Abstract: Late breaking general session
• Speaker: Raymond Douglas, M.D., OPTIC co-principal investigator and director of the orbital and thyroid eye disease program, Cedars-Sinai Medical Center
• Date: Friday, April 26, 2019
• Time: 11 a.m. – 12 p.m. PT

https://www.biospace.com/article/releases/horizon-pharma-plc-to-present-results-from-its-phase-3-teprotumumab-trial-optic-at-the-2019-american-association-of-clinical-endocrinologists-aace-scientific-and-clinical-congress/